Decline depth
-40.4%
From rolling 252-day high of $9.75, 200d ago.
Past the 40% Red List threshold.
-40.4%
from rolling 252-day high of $9.75 set 2025-12-22 · 200d ago
Current
$5.81
Decline depth
-40.4%
Decline σ
2.8σ
TFC
2/5 bearish
Rolling 252-day high
Up day
Down day
Last 90 trading days · data from Alpaca
Since tracking began
$NUVB has been tracked since 2026-03-01. It was down 40.1% from its 52-week high then — now down -40.4%.
Roughly where it joined — no recovery, no further break. It bottomed 58.5% below that high along the way.
Decline from the 52-week high as it stood on 2026-03-02 (fixed anchor) → today. Split-adjusted, Alpaca. Observed history, not a forecast.
Structural break signals
NUVB qualifies for the Red List on decline depth.
Time-frame continuity
2/5 bearish
Latest bar across daily/weekly/monthly/quarterly/yearly time frames. A bar counts as bearish when it's a 2-Down or a red 3.
Decline sigma
2.8σ
Drop from local high over the last 20 bars, expressed in units of the stock's typical daily volatility (4.3% per day).
The structural read
What price action says about NUVB.
NUVB qualifies for the Red List on decline depth — down -40.4% from its rolling 252-day high. Past the 40% threshold, the deepest tier in the taxonomy.
Earnings on file: 2026-05-04. Tiering is unaffected by earnings dates — listings reflect price structure only.
52-week range
52W low $1.57
51.8% of range
52W high $9.75
Sector context · Healthcare
132 other Healthcare tickers are on Broken Stocks.
61
Red List
34
Amber
37
Watch
-36.1%
Median decline
Worst in sector: UPB (-77.6%). Least-bad: ENTA (-20.1%). See all Healthcare listings →
Related — same sector
Closest decliners to NUVB
Red List
QURE
uniQure N.V.
Red ListRecovering
MLYS
Mineralys Therapeutics, Inc.
Red ListRecovering
SPOK
Spok Holdings, Inc.
Red List
AMPH
Amphastar Pharmaceuticals, Inc.
Red List
INBX
Inhibrx Biosciences, Inc.
Red List
ALNY
Alnylam Pharmaceuticals, Inc.
Questions about NUVB
What people ask.
Why is NUVB on Broken Stocks?
NUVB qualifies for the Red List on decline depth. It is down -40.4% from its rolling 252-day high of $9.75, set on 2025-12-22 — 200d ago.
Is NUVB a falling knife?
Not by the strict technical definition. NUVB is down -40.4% from its 52-week high, but that high was set 200d ago — more than 120 days. A falling knife is usually a recent breakdown from a fresh high, not an established multi-quarter downtrend. NUVB is still on the Red List for decline depth, but the freshness component of a falling knife is missing.
Is NUVB a buy?
Broken Stocks does not issue buy or sell recommendations. The list is a rules-based technical warning system. It tracks structural decline depth and recency — not company quality, management, fundamentals, or news. Always do your own research and consult a licensed advisor.
Where is NUVB trading inside its 52-week range?
At $5.81, NUVB sits 51.8% of the way from its 52-week low ($1.57) to its 52-week high ($9.75). A reading below 25% indicates price is hugging the bottom of the range; above 75%, the top.
How fast has NUVB been declining?
The current 40.4% decline accrued over 200d, which annualizes to roughly -73.7% per year. Annualized pace is a sanity check — a 30% decline in three months is a different signal than a 30% decline over two years.
How does NUVB compare to its sector?
There are 132 other Healthcare tickers on Broken Stocks: 61 Red, 34 Amber, 37 Watch, with 46 showing recovering structural signals. Median sector decline is -36.1% — NUVB's decline is deeper than the sector median.
Does NUVB's earnings date affect its tier?
No. Tiering is decided purely by decline depth and recency of the rolling-high date. The earnings date on file (2026-05-04) is shown for reference only — listings can move tier between scans based on closing prices, regardless of fundamentals or news events.